Failure Modes Effects Analysis of Morphine Prescribing

Size: px
Start display at page:

Download "Failure Modes Effects Analysis of Morphine Prescribing"

Transcription

1 Failure Modes Effects Analysis of Morphine Prescribing Hilary Writer MD FRCPC Elaine Wong BScPhm CPSI Patient Safety and Quality Improvement Forum,14 April 2010

2 Outline Rationale Medication Incidents with Morphine Morphine Administration Failure Modes Effects Analysis CHEO team and process Findings Recommendations and Future Plans

3 Why look at Morphine in Paediatrics In the paediatric literature, the reported prevalence of morphine adverse events ranges from 1% to 43% Esmail Z, Montgomery C, Courtrn C, Hamilton D, Kestle J. Efficacy and complications of morphine infusions in postoperative paediatric patients. Paediatric Anaesth. 1999; 9 (4):

4 Why look at Morphine in Paediatrics? Year 2008 Number of Patients <18 MORPHINE MEPERIDINE HYDROMORPHONE OXYCODONE METHADONE OXYMORPHONE Total Inpatients Receiving Opiate Agonists Brogan CHEO Brogan CHEO Brogan CHEO Brogan CHEO Brogan CHEO Brogan CHEO Brogan CHEO Brogan CHEO Brogan Narcotic Hospital Utilization

5 Why look at Morphine in Paediatrics? Anesthesia Patient Safety Foundation (APSF) There is still a low but unpredictable incidence of lifethreatening, opioid-induced respiratory depression in young healthy patients No patient shall be harmed by opioid-induced respiratory depression in the post-operative period Healthcare providers should have zero tolerance of respiratory morbidity and mortality associated with opioid use in the post-operative period because these events should be completely preventable

6 Why look at Morphine in Paediatrics? Medication Incidents ISMP 11 CAPHC member organizations found 305 reported incidents with an outcome of harm. Top 5 Medications with reports of incidents causing harm in a paediatric population Medication # Incidents (%) (Total n = 294) Morphine 26 (8.8) Potassium chloride 14 (4.8) Insulin 11 (3.7) Fentanyl 10 (3.4) Salbutamol 10 (3.4) ISMP Canada Safety Bulletin. Volume 9. Number 6. August 31 st, 2009

7 Why look at Morphine in Paediatrics? Because Accreditation Canada says so..

8 CHEO Internal Data 2406 safety reports posted (Jan 2007 Apr 2009) Of these, 671 (27.98%) were medication incidents 3.5% 5.7% Other medication incidents Other Opioids related Morphine related

9 Making Morphine Administration Safer Storage IDC Prescribing Monitoring Guidelines Monitoring

10 Overview of CHEO initiatives FMEA Pharmacy preparation of epidurals (2006) Morphine monitoring study (2006) Standard dose concentrations and calculation tool (2006) FMEA Epidural pump programming (2007) Development of PPO for PCA, continuous opioid infusions epidural infusions (2007) Independent Double Check/Double Check policy (2008) CAPHC/ISMP National Collaborative participation (2008) Late Career Nurse Initiative Morphine Administration (2009) Morphine IV bolus administration and Human Factors (2009)

11 FMEA Morphine Prescribing Team-based systematic and proactive approach for identifying the ways that a process or design can fail, why it might fail, the effects of that failure and how it can be made safer FMEA focuses on how and when a system will fail, not IF it will fail Practitioners in the system know the vulnerabilities and failure points

12 FMEA Process 1. Select a high risk process and assemble a team 2. Diagram the process 3. Brainstorm potential failure modes 4. Identify causes of failure modes 5. Prioritize failure modes 6. Re-design the process 7. Analyze and test the new process 8. Implement and monitor the new process Canadian Failure Mode and Effects Analysis Framework ISMP

13 FMEA Multidisciplinary Team Representation from Physicians (Critical Care Physician, Emergency Care Physician, Palliative Care, Chronic Pain & Symptom Management Physician, Anaesthesia & Acute Pain, Medical Resident, Surgery) Nursing Pharmacy Human Factor Engineering (Professor from Carleton University & Master s level student) Physicians were the core of the team Meetings did not take place without at least 3 physicians

14 Process Diagram Failure Modes Morphine prescribing Decision Information gathering MD Dose calculation Prescription written Order sheet/ppo available Reassess

15 Written Prescription Trailing zeros Allergies, wt Correct chart Math Legible Sig. Route Do not use Frequency, duration Drug name Legible order Correct pen Units, dose, range Signature quality ink Adjunct orders

16 FMEA: Morphine Prescribing 6 large category failure modes 8 total sub-categories of each failure mode 74 total causes across all failure modes Panel focused on the written prescription

17 Failure Modes Single Point Weakness A step so critical that its failure will result in a system failure or adverse event Prioritise Failure Modes: Severity (Score 1-5) Detectability (Score 1-4) Frequency (Score 1-5) Assign Risk Priority Number (RPN) where: RPN = Severity x Detectability x Frequency RPN > 48 Severity 5

18 Single Point Weaknesses

19 Severity 5 Weaknesses Severity 5 weaknesses

20 Risk Priority Number (RPN) 48 RPN 48

21 Strategies & Recommendations Development of corporate dosing guidelines Development of a verbal order policy Promotion of pre printed orders hospital wide Support for computerized physician order entry with forcing functions.

22 Possible Solutions: SPWs

23 Possible Solutions: Severity 5 Weaknesses Severity 5 weaknesses

24 Possible Solutions: Risk Priority Number (RPN) 48

25 Corporate Dosing Guidelines Development and dissemination of corporate dosing guidelines Audit of pharmacist interventions Review of safety reports Historical peak in July with new housestaff

26 Verbal Order Policy Development of corporate Policy Audit compliance with policy (including written documentation of read back ) Review of Safety reports Should Verbal Orders be allowed..?!

27 Promotion of Pre-Printed Orders Hospital Wide Audit of compliance with use of the pre-printed orders based on unit Initiate new PPO s where necessary

28 Computerized Aids Build prescribing templates with dosing guidelines, max/min alerts within computer systems Physician order entry IV infusion pumps Audit overrides in ordering/administering outside usual dosing guidelines

29 Future Directions Educational Programs In-person Web-based with testing Chart Audits Eg compliance with no dosing/duration range Pain scores E-clin Doc Monitoring data Human Factors Analysis

30 Hawthorne Effect? Reports to SRS April 09-Dec 09 Key Word Morphine 11 of 332 events 3.3%

31 CHEO Internal Data 2406 safety reports posted (Jan 2007 Apr 2009) Of these, 671 (27.98%) were medication incidents 3.5% 5.7% Other medication incidents Other Opioids related Morphine related

32 Comments or Questions?

Medication Safety Learning from Ontario Coroners Cases Focus on Opioids

Medication Safety Learning from Ontario Coroners Cases Focus on Opioids Medication Safety Learning from Ontario Coroners Cases Focus on Opioids Julie Greenall ISMP Canada March 6, 2013 Institute for Safe Medication Practices Canada 2012 ISMP Canada ISMP Canada is an independent

More information

Reducing the risk of patient harm: A focus on opioids

Reducing the risk of patient harm: A focus on opioids Reducing the risk of patient harm: A focus on opioids New York State Partnership for Patients (NYSPFP) Initiative Regional Educational Session November 2013 1 Disclosure Matthew Fricker, Matthew Grissinger,

More information

Medicines Optimisation Strategy

Medicines Optimisation Strategy Clinical Reducing Dosing Errors with Opioid Medicines (Controlled Drug SOP): Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic

More information

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Pain Management and Safe use of opioids in hospitals Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Bronx Care Health System Bronx Lebanon Hospital Concourse/ Fulton division, Nursing

More information

Key Findings from the ISMP Canada Safety Bulletins Drugs: Oversight, Safety and Supply OHA Educational Event November 20, 2015 Toronto, ON

Key Findings from the ISMP Canada Safety Bulletins Drugs: Oversight, Safety and Supply OHA Educational Event November 20, 2015 Toronto, ON Key Findings from the ISMP Canada Safety Bulletins Drugs: Oversight, Safety and Supply OHA Educational Event November 20, 2015 Toronto, ON David U President & CEO ISMP Canada Ontario Critical Incident

More information

PCA PRESCRIPTION is valid for a maximum of 4 days unless ceased earlier. Date: BINDING MARGIN - NO WRITING BINDING MARGIN - NO WRITING

PCA PRESCRIPTION is valid for a maximum of 4 days unless ceased earlier. Date: BINDING MARGIN - NO WRITING BINDING MARGIN - NO WRITING Attach ADR Sticker THESE INSTRUCTIONS EXPLAIN WHEN TO MAKE A CLINICAL REVIEW OR RAPID RESPONSE CALL, YOUR LOCAL ESCALATION PROTOCOL WILL EXPLAIN HOW TO MAKE A CALL PCA ALLERGIES & ADVERSE DRUG REACTIONS

More information

High-Alert Medications: A Look at the Safe Use of Narcotics. Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP)

High-Alert Medications: A Look at the Safe Use of Narcotics. Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP) High-Alert Medications: A Look at the Safe Use of Narcotics Allen Vaida, BSc, PharmD Institute for Safe Medication Practices (ISMP) Risk Identification in Healthcare The detection of a potential or actual

More information

Patient Harm with Opioids: Can We Truly Reduce the Risk? Ali-Reza Shah-Mohammadi, PharmD, MS, FISMP

Patient Harm with Opioids: Can We Truly Reduce the Risk? Ali-Reza Shah-Mohammadi, PharmD, MS, FISMP Patient Harm with Opioids: Can We Truly Reduce the Risk? Ali-Reza Shah-Mohammadi, PharmD, MS, FISMP Clinical Pharmacy Specialist Medication Safety Pharmacy Medication Management & Analytics The University

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and

More information

Long Term Care Formulary HCD - 08

Long Term Care Formulary HCD - 08 1 of 5 PREAMBLE Opioids are an important component of the pharmaceutical armamentarium for management of chronic pain. The superiority of analgesic effect of one narcotic over another is not generally

More information

An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center

An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center 1 TRICARE Eligible Beneficiaries Monthly Average, FY08 Retirees & Family

More information

Failure Mode and Effects Analysis (FMEA) Margaret Colquhoun

Failure Mode and Effects Analysis (FMEA) Margaret Colquhoun Failure Mode and Effects Analysis (FMEA) Margaret Colquhoun Consultant, ISMP Canada Director of Pharmacy & Professional Practice, Markham Stouffville Hospital What is Failure Mode and Effects Analysis

More information

PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION. Chronic Pain and Opiate Management Initiatives

PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION. Chronic Pain and Opiate Management Initiatives PACIFICSOURCE COMMUNITY SOLUTIONS AND GORGE COORDINATED CARE ORGANIZATION Chronic Pain and Opiate Management Initiatives Objectives To enhance understanding of current concepts, guidelines and risks of

More information

OPIOID PRESCRIBING BY ONTARIO DENTISTS

OPIOID PRESCRIBING BY ONTARIO DENTISTS OPIOID PRESCRIBING BY ONTARIO DENTISTS 2014-2016 2 TABLE OF CONTENTS 1. Executive summary 3 2. Introduction 4 3. Methods 5 4. Provincial data 7 5. Patients and dispense events 10 6. Specific Opioid Dispense

More information

Establishing Special and Common Cause Variation

Establishing Special and Common Cause Variation This presenter has nothing to disclose Establishing Special and Common Cause Variation Carol Haraden, PhD March 3, 2017 Framework for Clinical Excellence Patient Safety Psychological Safety Accountability

More information

Failure Mode Effect Analysis of Patient Controlled Epidural Analgesia

Failure Mode Effect Analysis of Patient Controlled Epidural Analgesia ISPUB.COM The Internet Journal of Anesthesiology Volume 37 Number 1 Failure Mode Effect Analysis of Patient Controlled Epidural Analgesia D Sanjekar, C Shekhar, H Stevens, N Mussadi Citation D Sanjekar,

More information

Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals

Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management The Johns Hopkins Hospital Objectives and Disclosures

More information

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid

Clinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Anticoagulation therapy : improving processes. Hilary Merrett and Fiona Gale, CHKS 18 th October 2010

Anticoagulation therapy : improving processes. Hilary Merrett and Fiona Gale, CHKS 18 th October 2010 Anticoagulation therapy : improving processes using risk management tools Hilary Merrett and Fiona Gale, CHKS 18 th October 2010 Risk management tools and anticoagulation therapy The applicable processes

More information

NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.

NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement. NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement May 2, 2018 1 May 2, 2018 2 Bureau Overview May 2, 2018 3 HISTORY 1850--Bureau

More information

Trust Guideline for the Management of Patient Controlled Analgesia (PCA) in Adults

Trust Guideline for the Management of Patient Controlled Analgesia (PCA) in Adults Patient Controlled Analgesia (PCA) in Adults A clinical guideline recommended for use For Use in: In all Clinical Areas By: Anaesthetists, Ward Nurses, Recovery Staff Acute Pain Service Staff For: Adult

More information

Appendix: Sample prescription form. The following sample prescription form gives examples of sections found in most hospital prescription forms.

Appendix: Sample prescription form. The following sample prescription form gives examples of sections found in most hospital prescription forms. The hands-on guide to practical prescribing Oliver Jones, Nandan Gautam Copyright 2004 by Blackwell Publishing Appendix: Sample prescription form The following sample prescription form gives examples of

More information

Report to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July Gosport Hospital Report & RUH Assurance

Report to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July Gosport Hospital Report & RUH Assurance Report to: Public Board of Directors Agenda item: 11 Date of Meeting: 25 July 2018 Title of Report: Status: Board Sponsor: Author: Appendices Gosport Hospital Report & RUH Assurance For Information Dr

More information

NBPDP Drug Utilization Review Process Update

NBPDP Drug Utilization Review Process Update Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates

More information

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04

Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical

More information

Drug Name (specify drug) Quantity Frequency Strength

Drug Name (specify drug) Quantity Frequency Strength Prior Authorization Form GEHA FEDERAL - STANDARD OPTION 1363-M Opioids IR MME Limit and Post Limit This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Analgesics: Management of Pain In the Elderly Handout Package

Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain In the Elderly Handout Package Analgesics: Management of Pain in the Elderly Each patient or resident and their pain problem is unique. A complete assessment should be performed

More information

Towards zero harm from prescribing errors. Gillian Cavell, Consultant Pharmacist in Medication Safety Kings College Hospital

Towards zero harm from prescribing errors. Gillian Cavell, Consultant Pharmacist in Medication Safety Kings College Hospital Towards zero harm from prescribing errors Gillian Cavell, Consultant Pharmacist in Medication Safety Kings College Hospital Outline How ambitious should patient safety goals be in relation to Medication

More information

Drug Name (specify drug) Quantity Frequency Strength

Drug Name (specify drug) Quantity Frequency Strength Prior Authorization Form MEDICA HEALTH PLAN IA EXCHANGE 1362-M Opioids IR Labeling Post Limit (HMF) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

High alert medicines

High alert medicines High alert medicines Dr Cristín Ryan, Royal College of Surgeons in Ireland Dr Ahmed Awaisu, College of Pharmacy, Qatar University Dr Bridget Javed, College of Pharmacy, Qatar University Dr Wessam El Kassem,

More information

D DAVID PUBLISHING. 1. Introduction. Shannon Inglet 1, Michael Curcio 2 and Lada Radetic 3

D DAVID PUBLISHING. 1. Introduction. Shannon Inglet 1, Michael Curcio 2 and Lada Radetic 3 Journal of Pharmacy and Pharmacology 6 (2018) 197-201 doi: 10.17265/2328-2150/2018.03.001 D DAVID PUBLISHING Evaluation of Opioid Reversal with Naloxone before and after Implementation of a Computerized

More information

Controlled Drug Process. Khoa Vo Masters candidate University of Canterbury

Controlled Drug Process. Khoa Vo Masters candidate University of Canterbury Controlled Drug Process Khoa Vo Masters candidate University of Canterbury Bachelor of Pharmacy (VN) PG Diploma in Palliative Care (NZ) Cancer Patients in Vietnam 250,000 of 89 million Increased by 150,000

More information

Safe use of opioids at Capital & Coast District Health Board (DHB)

Safe use of opioids at Capital & Coast District Health Board (DHB) Safe use of opioids at Capital & Coast District Health Board (DHB) Caroline Tilah Acting Director (Operations), Quality Improvement and Patient Safety (QIPS) Directorate CCDHB 21/10/2014 - Safe Use of

More information

1. Intrathecal must never be abbreviated to IT on a prescription form True / False

1. Intrathecal must never be abbreviated to IT on a prescription form True / False Appendix 1: Intrathecal SACT Assessment Questions Core General Questions must be completed by all staff. 1. Intrathecal must never be abbreviated to IT on a prescription form 2. Intrathecal SACT must be

More information

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Illinois Prescription Monitoring Program Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Agenda Provide an overview of the Illinois Prescription Monitoring Program

More information

Opioid Prescribing for Acute Pain

Opioid Prescribing for Acute Pain Patient Reference Guide Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Quality standards outline what high-quality care looks like. They focus on conditions or topics where

More information

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able

More information

8/30/2010. Structured:

8/30/2010. Structured: 3 4 5 6 7 8 9 Unit II Biopsychosocial Concepts Related to Health Care Communication Conflict Resolution - Huber Pain Management - LeMone Chp 9 Objectives Discuss importance of communication and documentation.

More information

Opioid Safety: The balance between pain, sleep and breathing. Presentation Objectives STEP 1: DEFINING THE PROBLEM

Opioid Safety: The balance between pain, sleep and breathing. Presentation Objectives STEP 1: DEFINING THE PROBLEM Opioid Safety: The balance between pain, sleep and breathing Richard Ensign, PharmD, BCPS Pharmacy Clinical Manager Intermountain Healthcare Richard.Ensign@imail.org (801) 442-3232 Presentation Objectives

More information

Ontario s Narcotics Strategy

Ontario s Narcotics Strategy Ontario s Narcotics Strategy Ontario Public Drug Programs Ministry of Health and Long-Term Care January 31, 2012 Ontario Harm Reduction Distribution Program Conference 2012 1 Background The Need for Action

More information

STARTER PACK: Webinar #1 ADE4 - OPIOIDS

STARTER PACK: Webinar #1 ADE4 - OPIOIDS STARTER PACK: Webinar #1 ADE4 - OPIOIDS Welcome to the Starter Pack Webinar #1 Why this is important Establishing a Team Best practices Understanding the Measures Completing a gap analysis First Steps

More information

Clinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol

Clinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol Clinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol 1. Aim/Purpose of this Guideline 1.1. To Provide safe and efficient administration of Opioids in Recovery.

More information

Fentanyl, Opioid Overdose and Naloxone

Fentanyl, Opioid Overdose and Naloxone Fentanyl, Opioid Overdose and Naloxone Opioid Agonist Therapy Conference Saskatoon, SK April, 2016 Declaration No conflict of interest. Consultant in Addiction Medicine, SHR. Chair, College of Physicians

More information

Is percocet stronger than demerol po

Is percocet stronger than demerol po Is percocet stronger than demerol po The Borg System is 100 % Is percocet stronger than demerol po Lateral plateau tibial fracture icd 10 code Is percocet stronger than demerol po Ladybug killer serial

More information

Objectives. Key Elements. ICAHN Targeted Focus Area: Drug Information and Drug Standardization and Distribution 3/24/2014

Objectives. Key Elements. ICAHN Targeted Focus Area: Drug Information and Drug Standardization and Distribution 3/24/2014 ICAHN Targeted Focus Area: Drug Information and Drug Standardization and Distribution Matthew Fricker, RPh, MS, FASHP Program Director, ISMP Rebecca Lamis, PharmD, FISMP Medication Safety Analyst, ISMP

More information

Beyond The Lockout Time. Kelcy Freeman, PharmD, BCPS April 20, 2017 REMEDI Pump Collaborative Spring Conference Chicago, IL

Beyond The Lockout Time. Kelcy Freeman, PharmD, BCPS April 20, 2017 REMEDI Pump Collaborative Spring Conference Chicago, IL Beyond The Lockout Time Kelcy Freeman, PharmD, BCPS April 20, 2017 REMEDI Pump Collaborative Spring Conference Chicago, IL Disclosure I am a full-time employee of Smiths Medical, global provider of medical

More information

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes.

Lumbar Fusion. Reference Guide for PACU CLINICAL PATHWAY. All patient variances to the pathway are to be circled and addressed in the progress notes. Reference Guide for PACU Lumbar Fusion CLINICAL PATHWAY All patient variances to the pathway are to be circled and addressed in the progress notes. This Clinical Pathway is intended to assist in clinical

More information

(30689) PROT Pain PCA Adult Patient Controlled Analgesia

(30689) PROT Pain PCA Adult Patient Controlled Analgesia Diagnosis Allergies Nursing Assess and Document PCA: 1. Assess and document pain rating, sedation level and respiratory rate every 2 hours; assess and document pain rating, sedation level and respiratory

More information

Mindful Prescribing for Acute Pain

Mindful Prescribing for Acute Pain Mindful Prescribing for Acute Pain London Hospitals as a Leader in Changing Opioid Prescribing Dr. Brian Rotenberg, MD MPH FRCSC MAC Vice Chair, St. Joseph s What about new starts? Source: Health Quality

More information

Opioid Pearls and Acute Pain Management

Opioid Pearls and Acute Pain Management Opioid Pearls and Acute Pain Management Jeanie Youngwerth, MD University of Colorado Denver Assistant Professor of Medicine, Hospitalist Associate Director, Colorado Palliative Medicine Fellowship Program

More information

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Opening Statement Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse Dr. Chris Simpson, President-elect

More information

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) Neonatal bstinence Syndrome Questions & nswers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012) For more information and to download a copy of the NS Clinical Practice Guidelines, please visit

More information

Conflict of Interest Declaration. High Risk Medications in the Hospital Pharmacy. According to. Learning Objectives. Medication Safety Organizations

Conflict of Interest Declaration. High Risk Medications in the Hospital Pharmacy. According to. Learning Objectives. Medication Safety Organizations Conflict of Interest Declaration High Risk Medications in the Hospital Pharmacy None to disclose Monika Gil, Pharm.D. Clinical Staff Pharmacist Rush University Medical Center Chicago, IL Learning Objectives

More information

ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health

ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE. Dr. David Williams Chief Medical Officer of Health ONTARIO S STRATEGY TO PREVENT OPIOID ADDICTION AND OVERDOSE Dr. David Williams Chief Medical Officer of Health National opioid-related mortality data, 2016 (Health Canada) Provincial Overdose Coordinator

More information

CLINICAL POLICY DEPARTMENT: Medical

CLINICAL POLICY DEPARTMENT: Medical IMPTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of currently available generally

More information

Location of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON

Location of initiative York Region Chronic Kidney Disease Program, Mackenzie Richmond Hill Hospital, Richmond Hill, ON Story # CSHP 015 objective Objective.1 - In 70% of ambulatory and specialized care clinics providing clinic care, pharmacists will manage medication therapy for clinic patients with complex and high-risk

More information

Medication-assisted opioid addiction treatments: OB/GYN

Medication-assisted opioid addiction treatments: OB/GYN 5/13/16se Medication-assisted opioid addiction treatments: OB/GYN In October 2002, the Food and Drug Administration (FDA) approved buprenorphine monotherapy product, Subutex, and a buprenorphine/naloxone

More information

RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM

RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM PROVIDING QUALITY CARE TO PAIN PATIENTS IN IOWA RELIEVING VIRGINIA S PAIN AND SUFFERING 3:45-4:45PM ACPE UAN: 107-000-14-016-L05-P Activity Type: Application-Based 0.1 CEU/1.0 hr Learning Objectives for

More information

Conversion chart from fentanyl to opana er

Conversion chart from fentanyl to opana er Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),

More information

Convert hydrocodone to ms contin

Convert hydrocodone to ms contin Convert hydrocodone to ms contin The Borg System is 100 % Convert hydrocodone to ms contin Jan 29, 2018. HYDROcodone (Vicodin, Lortab), -, 30-45 mg, -, 3-5. OXYmorphone (Opana), 1 mg, 10 mg, 10:1, 3-6.

More information

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation. Pharmacy Law 2016 Ronda H. Lacey, J.D., M.S. Pharm Disclosure Statement I have no conflicts of interest to disclose related to this presentation. Objectives At the conclusion of this continuing education

More information

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS

PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In

More information

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.

Oxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate. Page 1 of 7 Policies Repository Policy Title Policy Number Schedule II Prior Authorization FS.CLIN.16 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on

More information

Paediatric Prescribing Pocket Guide September 2014 (Version 1)

Paediatric Prescribing Pocket Guide September 2014 (Version 1) PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors

More information

Guideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use

Guideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document

More information

Controlled Substances: A survey of tools and resources required by hospital pharmacists

Controlled Substances: A survey of tools and resources required by hospital pharmacists Controlled Substances: A survey of tools and resources required by hospital pharmacists TABLE OF CONTENTS 2018. Canadian Society of Hospital Pharmacists About the survey 1 The Short and Snappy 1 What CSHP

More information

Patient Safety - IV Opioid Use in Hospitalized Patients. October 2014

Patient Safety - IV Opioid Use in Hospitalized Patients. October 2014 Patient Safety - IV Opioid Use in Hospitalized Patients October 2014 Objectives List reasons that necessitated development of risk assessment State a few risk factors or medical conditions from the IV

More information

Montgomery County Poisoning Death Review

Montgomery County Poisoning Death Review Wright State University CORE Scholar Unintentional Prescription Drug Poisoning Project Center for Interventions, Treatment and Addictions Research Montgomery County Poisoning Death Review - Center for

More information

2/9/2016. A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events. Objectives:

2/9/2016. A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events. Objectives: A Multi-Disciplinary Program to Decrease the Rate of Preventable Harm from Medication Events Michigan Pharmacist Association February 28, 2016 Steven Johnson, Pharm.D. Regional Clinical Director Gay Alcenius,

More information

High Alert Medications in the long-term care setting. Carrie Allen PharmD, CGP, BCPS, CCHP

High Alert Medications in the long-term care setting. Carrie Allen PharmD, CGP, BCPS, CCHP High Alert Medications in the long-term care setting Carrie Allen PharmD, CGP, BCPS, CCHP Who does this involve? Nurses Medication aides Pharmacies/pharmacists Medical Records and Data Entry Personnel

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Opioid Analgesics Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 11.17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the

More information

Understanding and Interpreting Adverse Drug Event (ADE) Readmission Reports

Understanding and Interpreting Adverse Drug Event (ADE) Readmission Reports Understanding and Interpreting Adverse Drug Event (ADE) Readmission Reports Lindsay Holland Director, Care Transitions Health Services Advisory Group (HSAG) October 24, 2017 Today s Webinar Objectives

More information

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. Managing Narcotics on Workers Comp Claims Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. October 21, 2014 Outline Rationale Scope list drug list Recommended

More information

Measure Abbreviation: PONV 01 (MIPS 430)

Measure Abbreviation: PONV 01 (MIPS 430) Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination

More information

Oxycontin to ms contin conversion chart

Oxycontin to ms contin conversion chart Oxycontin to ms contin conversion chart The Pink, One-Piece Wrap Style 1 ( Pink Stripe) Size - Small - Medium - Large Length (neck to base of tail) - 10 inches - 14 inches - 20 inches Width (without side.

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: HIM.PA.139 Effective Date: 12.01.17 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this policy

More information

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older

Opioid Prescribing for Acute Pain. Care for People 15 Years of Age and Older Opioid Prescribing for Acute Pain Care for People 15 Years of Age and Older Summary This quality standard provides guidance on the appropriate prescribing, monitoring, and tapering of opioids to treat

More information

Atlas of Healthcare Variation

Atlas of Healthcare Variation Atlas of Healthcare Variation Webinar 4: From atlases to action Make sure you have your pc and phone connected (see instructions emailed to you) You will be muted during the webinar to reduce background

More information

Narcotics Monitoring System (NMS) Update

Narcotics Monitoring System (NMS) Update Narcotics Monitoring System (NMS) Update DISCLOSURE OF COMMERCIAL SUPPORT This program has received no financial or in-kind support. Potential for conflict(s) of interest: None Faculty/Presenter Disclosure

More information

ADMINISTRATION OF INSULIN

ADMINISTRATION OF INSULIN STANDARD OPERATING PROCEDURE ADMINISTRATION OF INSULIN Issue History First issued April 2012 Issue Version Two Purpose of Issue/Description of Change Planned Review Date To promote the safe administration

More information

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group

Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical

More information

GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE

GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE 41.1 GENERAL PRINCIPLES The ICD 10 diagnostic criteria for dependency syndrome are listed in Table 41.1 below.

More information

The Morbidity and Mortality of Kansas Drug Epidemic

The Morbidity and Mortality of Kansas Drug Epidemic The Morbidity and Mortality of Kansas Drug Epidemic Fan Xiong, MPH Senior Epidemiologist Kansas Board of Pharmacy Kansas Data-Driven Prevention Initiative Program Kansas Department of Health and Environment,

More information

MORPHINE ADMINISTRATION

MORPHINE ADMINISTRATION Introduction Individualised Administration Drug of Choice Route of Administration & Doses Monitoring of Neonates & high risk patients Team Management Responsibility Morphine Protocol Flow Chart Introduction

More information

UCSF: 150 years in the making

UCSF: 150 years in the making Securing Hospital Approval for Ketamine use on the Wards: Challenges, Outcomes and Lessons Learned Acknowledgements Mark Schumacher Ph.D.,M.D. Professor and Chief, Division of Pain Medicine Dept. of Anesthesia

More information

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease

Evidence-Based Clinical Practice Guideline. Treatment & Management of Ocular Disease Evidence-Based Clinical Practice Guideline Treatment & Management of Ocular Disease Effective November 29, 2017 Treatment & Management Of Ocular Disease Clinical Practice Guideline The objective of this

More information

ISMP Targeted Medication Safety Best Practices. Christina Michalek, BS, RPh, FASHP

ISMP Targeted Medication Safety Best Practices. Christina Michalek, BS, RPh, FASHP ISMP 2018-2019 Targeted Medication Safety Best Practices Christina Michalek, BS, RPh, FASHP Objectives At the completion of this activity, you will be able to: Describe the most and least implemented Best

More information

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)? Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Opioids Long-Acting and Short-Acting (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Opioid Management of Chronic (Non- Cancer) Pain

Opioid Management of Chronic (Non- Cancer) Pain Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are

More information

Opioid Overdose Best Practices Guideline. Table of Contents. A. General description: B: Typical signs and symptoms:

Opioid Overdose Best Practices Guideline. Table of Contents. A. General description: B: Typical signs and symptoms: Opioid Overdose Best Practices Guideline Table of Contents A. General description B. Typical signs and symptoms C. Expected course D. Making the diagnosis E. Recommended treatment F. Criteria for hospital

More information

Intraspinal (Neuraxial) Analgesia Community Nurses Competency Test

Intraspinal (Neuraxial) Analgesia Community Nurses Competency Test Intraspinal (Neuraxial) Analgesia Community Nurses Competency Test 1 Intraspinal (Neuraxial) Analgesia for Community Nurses Competency Test 1) Name the two major classifications of pain. i. ii. 2) Neuropathic

More information

Insulin Administration Errors in Adult Community Nursing. Hedy Lehman Assistant Director of Professional Standards, Adult Community Nursing

Insulin Administration Errors in Adult Community Nursing. Hedy Lehman Assistant Director of Professional Standards, Adult Community Nursing Insulin Administration Errors in Adult Community Nursing Hedy Lehman Assistant Director of Professional Standards, Adult Community Nursing Organisational Background, Changes and Context Prior to April

More information

Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline

Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline Appendix 1. University of Minnesota Amplatz Children s Hospital Opioid Weaning Guideline 1. Pharmacist to order Narcotic Withdrawal Scores QH X 4 hours, then per table below: Narcotic Withdrawal Score

More information

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice

Essential Syringe Driver Training for T 34. Elaine Bird St Luke s Hospice Essential Syringe Driver Training for T 34 Elaine Bird St Luke s Hospice Aim For all practitioners to be accountable for their individual competence and capability when caring for a resident with a T34

More information

Review of Controlled Drugs and Substances Act

Review of Controlled Drugs and Substances Act Review of Controlled Drugs and Substances Act Canadian Medical Association: Submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations A

More information

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin. The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp

More information

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017 Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial

More information

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian 1. Introduction The provision of Substance Misuse (SM) services through

More information

Prior Authorization for Opioid Products Indicated for Pain Management

Prior Authorization for Opioid Products Indicated for Pain Management Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax

More information